Literature DB >> 31278583

True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends.

Tsutomu Kumamoto1, Yasunori Kurahashi1, Hirotaka Niwa1, Yasutaka Nakanishi1, Koichi Okumura1, Rie Ozawa1, Yoshinori Ishida1, Hisashi Shinohara2.   

Abstract

The definition of true esophagogastric junction (EGJ) adenocarcinoma and its surgical treatment are debatable. We review the basis for the current definition and the Japanese surgical strategy in managing true EGJ adenocarcinoma. The Siewert classification is a well-known anatomical classification system for EGJ adenocarcinomas: type II tumors in the region 1 cm above and 2 cm below the EGJ are described as "true carcinoma of the cardia". Coincidentally, this range matches gastric cardiac gland distribution. Conversely, Nishi's classification is generally used to describe EGJ carcinomas, defined as tumors with the center located within 2 cm above and 2 cm below the EGJ, regardless of their histological subtype. This range coincides with the extent of the lower esophageal sphincter combined with gastric cardiac gland distribution. The current Japanese surgical strategy focuses on the tumor range from the EGJ to the esophagus and stomach. According to previous studies, the strategy can be roughly classified into three types. The optimal surgical procedure for true EGJ adenocarcinoma is controversial. However, an ongoing Japanese nationwide prospective trial will help confirm the appropriate standard surgery, including the optimal extent of lymph node dissection.

Entities:  

Keywords:  Esophagogastric junction adenocarcinoma; Gastroesophageal junction adenocarcinoma; Siewert classification; Surgery

Year:  2019        PMID: 31278583     DOI: 10.1007/s00595-019-01843-4

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  10 in total

1.  Side-overlap esophagogastric tube (SO-EG) reconstruction after minimally invasive Ivor Lewis esophagectomy or laparoscopic proximal gastrectomy for cancer of the esophagogastric junction.

Authors:  Hisahiro Hosogi; Masazumi Sakaguchi; Daisuke Yagi; Ryohei Onishi; Yasuhiro Hashimoto; Yoshiharu Sakai; Seiichiro Kanaya
Journal:  Langenbecks Arch Surg       Date:  2021-11-13       Impact factor: 3.445

2.  Efficacy analysis of Cheng's GIRAFFE reconstruction after proximal gastrectomy for adenocarcinoma of esophagogastric junction.

Authors:  Zhiyuan Xu; Can Hu; Yanqiang Zhang; Ling Huang; Litao Yang; Jianfa Yu; Pengfei Yu; Jiahui Chen; Yian Du; Xiangdong Cheng
Journal:  Chin J Cancer Res       Date:  2022-06-30       Impact factor: 4.026

3.  Two updates on oesophagogastric junction adenocarcinoma from the fifth WHO classification: Alteration of definition and emphasis on HER2 test.

Authors:  Yunzhu Li; Jiayu Li; Jiman Li
Journal:  Histol Histopathol       Date:  2020-12-30       Impact factor: 2.303

4.  Lymphovascular Invasion as a Prognostic Factor in Non-Metastatic Adenocarcinoma of Esophagogastric Junction After Radical Surgery.

Authors:  Chengbin Zheng; Xingyu Feng; Jiabin Zheng; Qian Yan; Xu Hu; Huolun Feng; Zhenru Deng; Qianchao Liao; Junjiang Wang; Yong Li
Journal:  Cancer Manag Res       Date:  2020-12-14       Impact factor: 3.989

5.  Ideal Anatomical Landmark Points for Thoracic Esophagus Segmentation in the Chinese Population.

Authors:  Di Lu; Xiuyu Ji; Jintao Zhan; Jianxue Zhai; Tingxiao Fang; Siyang Feng; Xiguang Liu; Lin Yu; Zhiming Chen; Zhizhi Wang; Xuanzhen Wu; Sue Liu; Hua Wu; Kaican Cai
Journal:  Front Surg       Date:  2021-12-14

Review 6.  Evidence-based approach to the treatment of esophagogastric junction tumors.

Authors:  Francisco Schlottmann; María A Casas; Daniela Molena
Journal:  World J Clin Oncol       Date:  2022-03-24

Review 7.  Current treatments and outlook in adenocarcinoma of the esophagogastric junction: a narrative review.

Authors:  Fei Cao; Can Hu; Zhi-Yuan Xu; Yan-Qiang Zhang; Ling Huang; Jia-Hui Chen; Jiang-Jiang Qin; Xiang-Dong Cheng
Journal:  Ann Transl Med       Date:  2022-03

Review 8.  Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  Yi-Han Zheng; En-Hao Zhao
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

9.  Model established based on blood markers predicts overall survival in patients after radical resection of types II and III adenocarcinoma of the esophagogastric junction.

Authors:  Zhi-Jian Wei; Ya-Ting Qiao; Bai-Chuan Zhou; Abigail N Rankine; Li-Xiang Zhang; Ye-Zhou Su; A-Man Xu; Wen-Xiu Han; Pan-Quan Luo
Journal:  World J Gastrointest Surg       Date:  2022-08-27

10.  Oncologic Feasibility of Proximal Gastrectomy in Upper Third Advanced Gastric and Esophagogastric Junctional Cancer.

Authors:  Won-Gun Yun; Myung-Hoon Lim; Sarah Kim; Sa-Hong Kim; Ji-Hyeon Park; Seong-Ho Kong; Do Joong Park; Hyuk-Joon Lee; Han-Kwang Yang
Journal:  J Gastric Cancer       Date:  2021-06-23       Impact factor: 3.720

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.